Orforglipron

奥氟格列隆

Report date: 2026/04/27 20:02:09
NME

Base Information

Drug NameOrforglipron
Drug Alias NameGLP-1 receptor NPA (Eli Lilly and Company)奥格列龙Glucagon like peptide 1 receptor NPA (Eli Lilly and Company)奥福格列隆Foundayo +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightBody WeightObesity +[16] 
Global Approved IndicationsOverweightObesity
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2026/04/01
Country/TerritoryCzechiaBelgiumBulgaria +[40] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesChugai Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLilly Del Caribe IncEli Lilly And CompanyEli Lilly Nederland BV +[4] 
Inactive CompaniesN/A
Active IndicationsOverweightBody WeightObesity +[15] 
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG